JCA Readiness & PICO Strategy
Preparing for Joint Clinical Assessment starts long before submission.
Understanding likely evidence requirements early can help organisations reduce risk, align evidence planning and support successful value demonstration.
How do you prepare for JCA requirements that have limited precedent?
The European Joint Clinical Assessment is changing how evidence will be assessed across Europe, creating new considerations for evidence planning, synthesis requirements and value demonstration.
Organisations must make important decisions before formal scoping begins, often without knowing exactly which PICOs will be requested or how requirements may vary across member states.
Early insight into likely requirements can help teams prioritise evidence generation, address potential gaps and prepare more effectively for future assessments.
Powered by PICOSCAN®
PICOScan® helps organisations anticipate likely JCA evidence requirements before formal scoping begins.
By combining insights from clinical guidelines, HTA analogues, key opinion leaders and HTA stakeholders across Europe, PICOScan® provides early visibility of the evidence requirements that may influence future value demonstration, patient access and JSC planning.
Clinical Guidelines
By combining insights from clinical guidelines, HTA analogues, key opinion leaders and HTA stakeholders across Europe, PICOScan® provides early visibility of the evidence requirements that may influence future value demonstration, patient access and JSC planning.
HTA Analogues
By combining insights from clinical guidelines, HTA analogues, key opinion leaders and HTA stakeholders across Europe, PICOScan® provides early visibility of the evidence requirements that may influence future value demonstration, patient access and JSC planning.
Clinical Expert Perspectives
By combining insights from clinical guidelines, HTA analogues, key opinion leaders and HTA stakeholders across Europe, PICOScan® provides early visibility of the evidence requirements that may influence future value demonstration, patient access and JSC planning.
HTA Stakeholder Insight
By combining insights from clinical guidelines, HTA analogues, key opinion leaders and HTA stakeholders across Europe, PICOScan® provides early visibility of the evidence requirements that may influence future value demonstration, patient access and JSC planning.
Predicted PICO Requirements
By combining insights from clinical guidelines, HTA analogues, key opinion leaders and HTA stakeholders across Europe, PICOScan® provides early visibility of the evidence requirements that may influence future value demonstration, patient access and JSC planning.
Navigating uncertainty before JCA scoping begins
Understanding likely PICOs as early as possible helps to drive effective evidence generation and synthesis strategies.
Prioritisation and evidence planning become critical as the value demonstration strategy for an asset matures.
Identify potential evidence gaps, uncertainties and future requirements before they become access challenges.
Inform evidence generation, synthesis and planning activities while there is still an opportunity to act.
Focus time and investment on the evidence activities most likely to support future JCA and market access objectives.
Enabling JCA strategy
We apply our guiding framework, Explore • Build • Optimise, to help organisations anticipate likely PICO requirements, identify evidence risks and make better-informed JCA planning decisions.
Explore
Understand likely PICO expectations across European member states through targeted landscape review and early stakeholder insight
Build
Define evidence generation and synthesis requirements for predicted populations, comparators and outcomes
Optimise
Consolidate cross-market requirements to support value demonstration and alignment on European value and access strategy
Preparing for JCA?
Whether you're evaluating likely PICO requirements, planning evidence generation activities or preparing for future European HTA expectations, we're here to help.
JCA case studies
Explore how we've supported clients through JCA.
Phase III trial support and JCA planning for an innovative therapy for a rare neurological disorder
European HTA requirements and evidence generation/synthesis for a new gene therapy
European HTA integrated evidence generation planning for a paediatric orphan therapy
Assessment of ways of working and optimal cross-functional collaboration for delivery of the JCA
